Johnson & Johnson (JNJ) EBIT (2009 - 2026)

Johnson & Johnson (JNJ) has 18 years of EBIT data on file, last reported at $6.4 billion in Q1 2026.

• Quarterly EBIT rose 2.93% year-over-year to $6.4 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $40.1 billion (up 88.39% YoY) and the FY2025 annual result came in at $39.9 billion, up 89.98% from the prior year.
• EBIT eased to $6.4 billion in Q1 2026 per JNJ's latest filing, from $20.1 billion in the prior quarter.
• The five-year high for EBIT was $20.1 billion in Q4 2025, with the low at $3.6 billion in Q4 2024.
• Average EBIT over 5 years is $7.4 billion, with a median of $5.9 billion recorded in 2024.
• Year-over-year, EBIT tumbled 80.91% in 2024 and jumped 457.46% in 2025.
• Johnson & Johnson's EBIT stood at $5.3 billion in 2022, then jumped by 255.78% to $18.9 billion in 2023, then plunged by 80.91% to $3.6 billion in 2024, then jumped by 457.46% to $20.1 billion in 2025, then plunged by 68.28% to $6.4 billion in 2026.
• Business Quant data shows JNJ's EBIT at $6.4 billion in Q1 2026, $20.1 billion in Q4 2025, and $7.0 billion in Q3 2025.